NCT05519865 2026-04-20
A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC
Chipscreen Biosciences, Ltd.
Phase 2 Completed
Chipscreen Biosciences, Ltd.
RemeGen Co., Ltd.
BeOne Medicines
ImmunityBio, Inc.
Tianjin Medical University Cancer Institute and Hospital
BeOne Medicines
Novartis